Auna (AUNA) Q2 2026: 9% FX-Neutral Revenue Growth Amid Margin Pressures and Strategic Capacity Expansion
Auna delivered sustained revenue growth driven by volume and high-complexity service expansion across Latin America, despite adjusted EBITDA pressures from service mix and billing reconciliations. The company’s strategic investments in capacity and technology position it for improved profitability and leverage reduction ahead. Operational improvements in Mexico and Colombia underpin confidence in meeting full-year guidance.
Summary
- Regional Growth Momentum: Volume-driven expansion in high-complexity care underpins multi-market revenue gains.
- Margin Headwinds from Mix and Penalties: Temporary adjusted EBITDA pressures reflect investments and billing reconciliations.
- Strategic Capacity and Technology Buildout: New facilities and advanced treatment tech set stage for sustained competitive advantage.
Business Overview
Auna operates a leading healthcare platform in Latin America, with significant presence in Mexico, Peru, and Colombia. Its business model integrates healthcare services, insurance, and oncology care, generating revenue primarily from patient volumes, insurance memberships, and high-complexity treatments. The company’s major segments include Healthcare Services and Oncosalud, its oncology insurance arm, with Peru representing the largest revenue and EBITDA contributor, followed by Mexico and Colombia.
Performance Analysis
Auna reported a 9% increase in consolidated revenue on a foreign exchange-neutral basis, reaching S/1,238 million in Q2 2026. This growth was driven by higher patient volumes and an improved mix favoring high-complexity services such as oncology and surgeries across all three markets. Mexico’s healthcare network saw a 7% rise in surgeries and a 20% increase in oncology treatments compared to Q1 2026, supported by improved insurer tier classifications and expanded oncology offerings. Peru’s revenue grew 8%, fueled by membership gains and higher-value procedures, while Colombia’s 13% revenue growth reflected successful diversification into risk-sharing contracts and reduced exposure to financially distressed payors.
Despite top-line strength, consolidated adjusted EBITDA declined 9% FX-neutral year-over-year to S/227 million, with margin contraction to 18.4%. The decline reflected temporary margin pressures from service mix shifts and investments in medical talent in Mexico, onboarding costs and billing penalties in Peru, and wage increases alongside risk-sharing contract stabilization costs in Colombia. Sequentially, adjusted EBITDA improved 3%, signaling operational progress. Cash flow generation was a standout, with operating cash flow up 45% and free cash flow surging 181% year-over-year due to disciplined working capital management and improved collections, notably in Colombia. Leverage improved to 3.6x net debt to EBITDA, moving closer to the medium-term target below 3.0x.
- Volume and Mix Expansion: Growth in high-complexity oncology and surgeries drove revenue gains across all regions.
- Temporary Margin Pressure: Investments in talent and billing-related penalties, especially in Peru, compressed adjusted EBITDA.
- Robust Cash Flow and Deleveraging: Strong working capital discipline and collections improved cash flow and leverage metrics.
Overall, Auna’s financial performance reflects a business investing through near-term challenges to capture sustainable growth opportunities in Latin America’s evolving healthcare landscape.
Executive Commentary
"Our second quarter results demonstrate sustained commercial momentum across AUNA's regional healthcare platform and substantial progress in the operational enhancements we implemented last year, particularly in Mexico. Despite margin pressures, the underlying performance remains robust, and we continue to see strong demand across the platform."
Jesús Zamora, Executive Chairman and President
"The decrease in adjusted EBITDA reflects lower contribution margins related to Mexico's service mix and our growth investments in talent, alongside billing impacts in Peru. We expect adjusted EBITDA to improve sequentially in the second half, driven by volume growth, contractual price adjustments, and stabilization of new contracts."
Gisele Remy, Chief Financial Officer and Executive Vice President
Strategic Positioning
1. Focused Expansion in High-Complexity Care
Auna is strategically prioritizing high-complexity services, including oncology and surgeries, across its markets. Mexico’s network is benefiting from improved insurer tier classifications and oncology offerings, while Peru’s integrated model leverages membership growth and higher-value procedures. Colombia is scaling risk-sharing contracts that now represent 24% of segment revenue, enhancing revenue quality and cash flow predictability.
2. Capacity and Technology Investments to Support Growth
The company is expanding capacity with minimal incremental capital expenditure, such as reactivating ICU and hospitalization beds in Colombia and inaugurating a new clinical facility in Lima Sur, Peru. Additionally, Auna is deploying advanced technology like the Elekta EVO linear accelerator in Monterrey and a Versius SP4 robotic system in Peru to strengthen clinical capabilities and operational efficiency.
3. Operational Enhancements and Talent Investments
In Mexico, Auna is onboarding high-productivity physicians with stringent criteria and improving nursing coverage, supporting volume growth and service quality. Talent investments, although pressuring margins short term, are intended to underpin sustained growth and improved service delivery.
4. Financial Discipline and Leverage Reduction
Strong cash flow generation and working capital management have enabled Auna to reduce leverage to 3.6x net debt to EBITDA. The company targets further deleveraging to below 3.0x, balancing growth investments with financial prudence.
5. Billing Cycle Improvements and Risk Mitigation
After elevated billing penalties in Peru due to prior years’ receivables reconciliation, Auna has accelerated billing cycle compression and strengthened financial controls to mitigate future penalty exposure. Management expects these reconciliations to conclude within 2026, normalizing profitability.
Key Considerations
Auna’s Q2 results highlight the complexities of scaling a multi-country healthcare platform amid evolving payer dynamics and regulatory environments. The company’s focus on high-complexity care and risk-sharing contracts positions it to capitalize on growing demand for specialized services. However, margin pressures from investments and billing reconciliations warrant close monitoring.
Key Considerations:
- Service Mix Impact: Shifts toward higher complexity services boost revenue but can compress margins initially due to higher variable costs.
- Billing Reconciliation Risks: Penalties in Peru related to prior periods affect adjusted EBITDA; ongoing controls aim to prevent recurrence.
- Working Capital Sustainability: Improvements in receivables and payables management appear sustainable, supporting strong cash flow.
- Regulatory and Political Environment: New administrations in Peru and Colombia are viewed positively for private sector healthcare participation and investment.
- Capital Allocation Discipline: Selective capacity expansions and technology investments emphasize capital efficiency and competitive differentiation.
Risks
Risks include potential delays or challenges in billing reconciliation settlements, wage inflation pressures especially in Colombia, and regulatory changes that could affect payer mix or reimbursement rates. Additionally, macroeconomic volatility and currency fluctuations remain factors affecting financial results and debt servicing costs.
Forward Outlook
For Q3 2026, Auna anticipates continued revenue growth driven by volume recovery in Mexico and operational progress in Colombia. Adjusted EBITDA is expected to improve sequentially as contractual price increases take effect and risk-sharing contracts stabilize.
- Revenue growth near the midpoint of 10% to 14% FX-neutral guidance for full-year 2026, approximately 12%.
- Adjusted EBITDA growth expected toward the low end of the guidance range, excluding billing penalty impacts.
Capital expenditures guidance remains at approximately 4% of revenues. Free cash flow is expected to exceed original internal expectations, supporting further deleveraging.
Takeaways
Auna’s second quarter reflects a healthcare platform balancing growth with operational and financial discipline amid regional market complexities.
- Growth Anchored by High-Complexity Services: Oncology and surgical volumes are key drivers, supported by strategic insurer relationships and membership expansion.
- Margin Pressure Reflects Strategic Investments and One-Time Impacts: Temporary EBITDA headwinds are linked to talent investments and billing reconciliations, expected to normalize.
- Forward Focus on Capacity, Technology, and Cash Flow: Investments in advanced treatment capabilities and capacity expansions position Auna for sustainable growth and margin recovery.
Conclusion
Auna’s Q2 2026 results underscore robust revenue growth driven by high-complexity care across Latin America, tempered by short-term margin pressures from investments and billing reconciliations. The company’s strategic capacity expansions, technology deployment, and disciplined cash flow management strengthen its position to meet full-year guidance and medium-term leverage targets.
Industry Read-Through
Auna’s performance highlights broader Latin American healthcare sector trends including the shift toward value-based care models, risk-sharing contracts, and the growing importance of high-complexity services like oncology. The company’s experience with billing reconciliations and payer mix diversification provides a case study for peers navigating regulatory and financial pressures. Additionally, Auna’s investments in advanced technology and asset-light capacity expansion reflect industry-wide moves to improve clinical outcomes while managing capital intensity.